Vivani Medical

Executive Summary

Vivani Medical is a publicly traded biotechnology company developing miniaturized, long-term biopharmaceutical implants designed to improve medication adherence and patient outcomes. The company's proprietary platform aims to deliver sustained-release therapies for chronic conditions, reducing the burden of frequent injections. With a focus on obesity and metabolic diseases, Vivani leverages its implant technology to provide consistent drug exposure over extended periods, potentially enhancing efficacy and patient compliance. Vivani's lead pipeline candidate is a weekly semaglutide injection for obesity and overweight, currently in a Phase 1 clinical trial (NCT07430059) that began recruiting in April 2026 and is expected to complete by September 2026. The company also has a completed Phase 1 trial evaluating a combination of exenatide extended release and semaglutide for overweight and type 2 diabetes. Given its early-stage pipeline and modest valuation of approximately $91 million, Vivani represents a high-risk, high-reward opportunity in the drug delivery space.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 top-line data readout for semaglutide implant in obesity60% success
• Q4 2026Initiation of Phase 2 study for lead candidate40% success
• TBDPotential partnership or licensing deal for implant platform30% success